We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red. The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The interactive Survival Scatter plot allows for the cutoff to be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Survival analysis". Under the Survival Scatter plot the p-score landscape is shown together with the difference in median between survival time for patients who have died with respect to high and low expression. This is intended to aid the user in exploring custom cutoffs.
Individual patient data is displayed in an interactive plot and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off).
Based on the FPKM value of each gene, we classified the patients into two groups and examined their prognoses. In the analysis, we excluded genes with low expression, i.e., those with a median expression among samples less than FPKM 1. The prognosis of each group of patients was examined by Kaplan-Meier survival estimators, and the survival outcomes of the two groups were compared by log-rank tests. To choose the best FPKM cut-offs for grouping the patients most significantly, all FPKM values from the 20th to 80th percentiles were used to group the patients, significant differences in the survival outcomes of the groups were examined and the value yielding the lowest log-rank P value is selected.
: 243.6
Median expression: N/A
Median follow up time: N/A P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A 5-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A 5-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average FPKM
263.6
Number of samples
64
Samples
Sample
Description
FPKM
TCGA-KM-8639-01A
67 years, male, white, stage:i, alive, 953 days
874.1
TCGA-KN-8418-01A
41 years, female, white, stage:ii, alive, 3935 days
587.8
TCGA-KL-8344-01A
51 years, male, white, stage:iii, alive, 876 days
492.9
TCGA-KN-8423-01A
44 years, male, white, stage:i, alive, 788 days
489.4
TCGA-KN-8429-01A
38 years, female, white, stage:iii, alive, 2650 days
476.7
TCGA-KL-8339-01A
67 years, male, white, stage:iv, dead, 855 days
458.9
TCGA-KM-8477-01A
56 years, male, white, stage:i, alive, 1553 days
436.7
TCGA-KL-8330-01A
44 years, female, black or african american, stage:ii, alive, 3304 days
395.1
TCGA-KL-8325-01A
56 years, female, white, stage:ii, dead, 725 days
389.9
TCGA-KN-8421-01A
48 years, female, white, stage:ii, alive, 2674 days
374.3
TCGA-KL-8329-01A
57 years, female, asian, stage:i, alive, 2752 days
371.5
TCGA-KL-8343-01A
72 years, male, white, stage:iii, dead, 2172 days
369.1
TCGA-KL-8332-01A
55 years, male, white, stage:i, alive, 2582 days
366.4
TCGA-KN-8424-01A
42 years, female, white, stage:i, alive, 1983 days
361.7
TCGA-KL-8340-01A
34 years, male, white, stage:ii, alive, 2024 days
357.7
TCGA-KM-8440-01A
37 years, male, black or african american, stage:iii, alive, 1366 days
354.9
TCGA-KO-8417-01A
30 years, female, white, stage:i, alive, 2815 days
345.1
TCGA-KN-8435-01A
59 years, male, white, stage:ii, alive, 3498 days
342.5
TCGA-KN-8419-01A
43 years, male, black or african american, stage:ii, alive, 714 days
339.7
TCGA-KL-8334-01A
37 years, female, white, stage:iii, alive, 2949 days
327.9
TCGA-KL-8336-01A
51 years, female, white, stage:iv, dead, 920 days
308.5
TCGA-KO-8413-01A
46 years, male, white, stage:i, alive, 3038 days
308.1
TCGA-KL-8328-01A
60 years, male, white, stage:ii, alive, 3127 days
304.8
TCGA-KN-8426-01A
50 years, male, white, stage:iv, alive, 108 days
304.7
TCGA-KO-8414-01A
50 years, female, white, stage:ii, alive, 3212 days
299.9
TCGA-KN-8432-01A
86 years, female, white, stage:ii, alive, 76 days
291.0
TCGA-KL-8323-01A
57 years, female, white, stage:iii, dead, 1158 days
268.2
TCGA-KN-8431-01A
35 years, female, stage:ii, alive, 588 days
266.7
TCGA-KL-8338-01A
51 years, male, white, stage:iii, alive, 2633 days
260.5
TCGA-KO-8410-01A
74 years, female, white, stage:i, alive, 3136 days
246.9
TCGA-KO-8408-01A
47 years, male, white, stage:iii, dead, 507 days
244.7
TCGA-KL-8345-01A
75 years, male, white, stage:iii, alive, 1665 days
242.5
TCGA-KO-8405-01A
29 years, male, white, stage:iii, alive, 3056 days
240.8
TCGA-KM-8442-01A
38 years, male, stage:ii, alive, 1437 days
233.0
TCGA-KO-8407-01A
42 years, male, white, stage:ii, alive, 2820 days
222.2
TCGA-KL-8335-01A
68 years, male, white, stage:iii, alive, 2815 days
219.7
TCGA-KL-8337-01A
26 years, male, black or african american, stage:ii, alive, 1364 days
217.1
TCGA-KM-8441-01A
61 years, female, white, stage:i, alive, 876 days
204.2
TCGA-KN-8434-01A
65 years, female, white, stage:ii, alive, 1797 days
202.3
TCGA-KN-8425-01A
53 years, male, white, stage:i, alive, 3179 days
196.6
TCGA-KL-8333-01A
69 years, male, white, stage:ii, alive, 2991 days
192.0
TCGA-KL-8331-01A
48 years, female, white, stage:ii, alive, 3010 days
191.3
TCGA-KL-8341-01A
41 years, male, asian, stage:iv, dead, 754 days
186.9
TCGA-KL-8342-01A
45 years, female, white, stage:ii, alive, 2248 days
186.5
TCGA-KO-8411-01A
58 years, male, white, stage:i, alive, 3958 days
184.8
TCGA-KO-8406-01A
17 years, female, white, stage:i, alive, 3145 days
183.2
TCGA-KN-8437-01A
42 years, female, white, stage:i, alive, 3068 days
172.5
TCGA-KM-8439-01A
30 years, male, white, stage:i, alive, 708 days
166.9
TCGA-KO-8409-01A
69 years, male, white, stage:ii, alive, 3180 days
165.1
TCGA-KL-8346-01A
62 years, male, white, stage:ii, alive, 1897 days
160.2
TCGA-KO-8416-01A
41 years, male, white, stage:iii, alive, 2752 days
155.9
TCGA-KM-8443-01A
58 years, male, white, stage:ii, alive, 1520 days
140.8
TCGA-KL-8326-01A
69 years, male, white, stage:iii, alive, 3322 days
139.0
TCGA-KN-8428-01A
71 years, male, white, stage:ii, dead, 1590 days
135.9
TCGA-KL-8324-01A
67 years, female, white, stage:ii, alive, 4676 days
134.2
TCGA-KN-8436-01A
63 years, male, white, stage:ii, alive, 1288 days
131.8
TCGA-KO-8415-01A
44 years, female, white, stage:i, alive, 2939 days
122.7
TCGA-KM-8438-01A
45 years, female, white, stage:ii, alive, 4622 days
117.4
TCGA-KO-8403-01A
49 years, male, white, stage:i, alive, 3208 days
105.6
TCGA-KN-8433-01A
46 years, female, white, stage:iii, alive, 341 days
96.5
TCGA-KM-8476-01A
47 years, male, white, stage:i, alive, 3745 days
77.7
TCGA-KO-8404-01A
78 years, male, white, stage:iv, dead, 325 days
56.9
TCGA-KN-8427-01A
54 years, male, white, stage:iv, alive, 30 days
47.3
TCGA-KL-8327-01A
46 years, female, white, stage:i, alive, 4169 days
The Human Protein Atlas project is funded
MENU
